Kornimate/medical-research-clean huggingface dataset:
the effect of clinical parameters on muscle oxygenation in patients with copd

Conditions: Chronic Obstructive Pulmonary Disease; Muscle Oxygenation; Disease Severity; Respiratory Function

Summary: the aim of this study is to examine the peripheral muscle oxygenation of patients with chronic obstructive pulmonary disease at rest, during submaximal exercise and recovery, and to examine the effects of disease severity and respiratory functions on peripheral muscle oxygenations. in this study, the effect of disease severity and respiratory problems on peripheral muscle metabolism of patients with copd will be explained.


Eligibility criteria:
inclusion criteria: * being diagnosed with copd (according to gold staging: gold 1, gold 2, gold 3, gold 4) * being between the ages of 40-80 * body mass index \<35 * not having an acute exacerbation in the last 3 months exclusion criteria: * patients who do not want to participate in the study * arthritis causing weakness in the lower extremity, neurological disease, deep vein thrombosis, peripheral arterial disease, muscle weakness, fracture etc. patients with the condition * common diseases such as malignancy, pulmonary embolism, vasculitis, collagen tissue diseases, interstitial fibrosis, severe pneumonia patients with parenchymal destruction * patients with severe dyspnea and hemodynamic instability who cannot perform the 6 minute walk test

Keywords: chronic obstructive pulmonary disease muscle oxygenation disease severity respiratory function
a study of the natural history of participants with lgmd2e/r4, lgmd2d/r3, lgmd2c/r5, and lgmd2a/r1 ≥ 4 years of age, who are managed in routine clinical practice

Conditions: Limb-girdle Muscular Dystrophy

Summary: this study will follow participants who are screened and confirmed with a genetic diagnosis of limb-girdle muscular dystrophy type 2e (lgmd2e/r4), limb-girdle muscular dystrophy type 2d (lgmd2d/r3), limb-girdle muscular dystrophy type 2c (lgmd2c/r5), or limb-girdle muscular dystrophy type 2a (lgmd2a/r1). these enrolled participants will be followed to evaluate mobility and pulmonary function for up to 5 years after enrollment for participants with lgmd2c/r5, lgmd2d/r3, and lgmd2e/r4 with a north star assessment for dysferlinopathy (nsad) ≥ 25 at baseline, up to 3 years for participants with lgmd2c/r5, lgmd2d/r3, and lgmd2e/r4 with a nsad \< 25 at baseline, and up to 3 years for participants with lgmd2a/r1. additional participant data will be collected from the time the individual began experiencing lgmd symptoms to the present.


Eligibility criteria:
inclusion criteria: * male or female participant ≥ 4 years of age who demonstrate symptoms of lgmd2e/r4, lgmd2d/r3, lgmd2c/r5, or lgmd2a/r1 in the opinion of the investigator (eg, muscle weakness, loss of function, delayed milestones). * confirmed clinical and genetic diagnosis of lgmd2e/r4, lgmd2d/r3, lgmd2c/r5, or lgmd2a/r1. exclusion criteria: * demonstrates cognitive delay or impairment that could confound motor development, in the opinion of the investigator. * has a medical condition, in the opinion of the investigator, that might compromise participants ability to comply with study requirements. * is participating in other interventional study(ies) at the time of enrollment in this study.

Keywords: north star assessment for dysferlinopathy (nsad) performance of upper limb (pul) pulmonary function tests (pfts) ambulatory non-ambulatory limb-girdle lgmd sarcoglycanopathy β -sarcoglycan muscular dystrophy α -sarcoglycan γ -sarcoglycan lgmd-2d/r3 lgmd-2e/r4 lgmd-2c/r5 lgmd2a/r1 clinical outcomes assessment
pertussis vaccination in pregnant women

Conditions: Pertussis

Summary: brief summary: the study compares four models of pertussis vaccination dispensation to pregnant women on the vaccine coverage obtained. in addition, the cost of the different models of vaccination will be evaluated.

this is a quasi-experimental study with a non-equivalent control group in pregnant women, taking place in 4 regions of québec (montréal, montérégie, capitale-nationale, mauricie). four models of vaccine dispensation will be evaluated: one university hospital around gestational diabetes screening, local health and social services centres (cslc) and a high volume clinic. 250 participants will be recruited in each of the four types of centres. in addition, the study will also evaluate the costs incurred by all those involved in the pertussis vaccination program for pregnant women as well as the cost per woman vaccinated. health professionals: 15 to 20 health professionals involved in providing immunization services to pregnant women: obsterician-gynaecologists, family doctors and nurses in participating clinics will be interviewed to evaluate their knowledge, attitudes and professional practises regarding pertussis vaccination during pregnancy. evaluating the cost: a detailed costing approach (micro-costing) will be used. time and movement will be studied by direct observation using a grid on an electronic file in each of the 5 environments studied in order to identify the services and activities carried out as well as to determine the resources involved in the implementation of these services and activities. three typical vaccination days will be chosen to make these observations, in each of the four study environments. the main activities observed will be related to preparations for vaccination up to the vaccination itself (informed consent, injection, etc.), the capture of vaccination data the management of vaccines and equipment, clinical manifestations, etc. if necessary, the people observed can be interviewed directly to better understand the activities or services provided. otherwise, some questions may be included in the interviews described above. the major cost categories that will be evaluated for each of the delivery modalities are human resources and supplies. the cost components listed are: nursing time (immunization / training), coordination time, support staff time, office supplies, vaccine storage equipment, vaccine transportation equipment, vaccine transportation, health and safety equipment, emergency, single-use vaccination equipment and others. with regard to the costs borne by women, the main categories of variables evaluated will be: the time spent making appointments and attending vaccination appointments, working time lost, if any, transportation, childcare and other expenses

Eligibility criteria:
inclusion criteria: * pregnant women at least 18 years old who speak english or french * signed informed consent exclusion criteria: -

Keywords: pertussis immunization coverage vaccination pregnant women quebec
effect of mouthwash in reducing the symptoms associated with flu and cold viruses

Conditions: Healthy

Summary: the aim of this study will be to evaluate the efficacy of regular cleaning of the oropharynx (via gargling) on the incidence of symptoms associated with flu and colds. the working hypothesis is that there will be a significant reduction in symptoms associated with flu and colds after using the mouthwash product, compared to the experimental control regime. a total of 150 individuals will be randomized to one of the two experimental regimens and followed for a period of 90 days. the experimental regimen consists of toothbrushing followed by gargling with a cetylpyridinium chloride (cpc) (0.075%) and zinc containing alcohol free rinse and the control regimen consists of toothbrushing alone. participants will be instructed to brush their teeth twice a day for two minutes. those allocated to the test regime will gargle with 20 ml of the mouthwash after each brushing. at the initial visit, participants will receive the products and instructions for use, as well as a daily log questionnaire. participants will be asked to send their daily records once a week, using a messaging application. the proportion of days without any of the evaluated symptoms will be used as the main outcome. in addition, soft and hard tissue exams will be performed at the initial consultation, after 30 and 90 days of follow-up by a blinded researcher. potential adverse events will be collected throughout the study. the groups will be compared using the chi-square test and one-way analysis of variance (anova) will be used to compare the treatment group symptom rates between groups. the significance level will be set at 95%.


Eligibility criteria:
inclusion criteria: * good systemic general health as determined by study investigators; availability of 90 days to participate in the study; exclusion criteria: 1. those participating in any other clinical study; 2. pregnant or breastfeeding; 3. presence a history of allergies to oral hygiene products, personal hygiene products, or their ingredients; 4. have mouth irritation or use oral anesthetic sprays; 5. have diabetes; 6. be undergoing extensive dental treatment or oral surgery during the study; 7. present immunocompromised (hiv, aids, immunosuppressive drug therapy); 8. use complete dentures; 9. do not have carpal tunnel syndrome or arthritis in the hands. 10. participant who substantially fails to follow the required protocols; 11. participant who fails to attend scheduled appointments; 12. participant who is treated, during the study period, with medications that may interfere with the parameters being analyzed in the study; 13. participant who is treated by a medical or dental service, and this may interfere with the parameters being analyzed in the study; 14. participant who develops serious adverse reactions. 15. the participant who chooses to terminate their participation in the study; 16. participant reports being pregnant during the study.
hand-held dynamometer assessment: e-sports grip-asymmetry index as a predictor of wrist pain

Conditions: Wrist Injuries

Summary: this cross-sectional study investigates whether a simple grip-asymmetry index (gai) can predict self-reported wrist pain in professional e-sports athletes. professional gamers (aged 18-30) who play at least 35 hours per week will be assessed using a jamar dynamometer to measure maximal grip force in both hands. the study will compare gai between two groups: those with wrist pain (≥3/10 on visual analog scale during play) and those without pain. a gai cutoff value for predicting wrist pain risk will be established through roc analysis, with additional factors such as gaming hours, bmi, and sex incorporated into a multivariable logistic regression model.


Eligibility criteria:
inclusion criteria: * professional e-sports athletes (receiving compensation for gaming activities) * age between 18 and 30 years * gaming for at least 35 hours per week * for pain group: reports wrist pain rated ≥3/10 on vas during gaming activities * for no-pain group: reports minimal to no wrist pain (\<3/10 on vas) during gaming activities exclusion criteria: * history of neurologic disease * history of rheumatic disease * previous wrist surgery * recent wrist trauma (within 3 months) * use of pain medication within 24 hours of assessment * inability to perform grip strength testing
importance of dosing regimen for the effect of vitamin d supplementation

Conditions: Hypovitaminosis D

Summary: vitamin d is a hormone with effects not only on the skeleton, but on most tissues in the body. lack of vitamin d is associated with cardio-vascular disease (cvd), type 2 diabetes, cancer, infectious and immunological diseases, as well as risk factors for these diseases. however, intervention studies with vitamin d have been inconclusive regarding diseases and risk factors. this could be due to inclusion of subjects already vitamin d sufficient, and short and underpowered studies. in addition, there are indications that the dosing regimens may be important, so that daily doses with vitamin d are more efficient than intermittent doses, which so far have been generally used. this could be related to the concentration of circulating and thereby intracellular vitamin d concentrations, which probably is dependent on daily vitamin d doses. this will be tested in the present study where 60 subjects will be randomized to vitamin d 160 000 once, vitamin d 4000 iu/day, or placebo for four weeks. the primary endpoints will be effects on serum hepcidin and plasma cathelicidin after 4 weeks, with effects on serum pth, rna expression and microrna in peripheral blood, telomerase activity in peripheral blood mononuclear cells and the ration between serum 1,25(oh)2d and 24,25(oh)2d as secondary endpoints.


Eligibility criteria:
inclusion criteria:- males and females 20 - 70 years * 20 kg/m2 \> bmi \< 35 kg/m2 * systolic bp \< 175 mmhg, diastolic bp \< 105 mmhg * serum 25(oh)d level \< 50 nmol/l. serum 25(oh)d \< 50 nmol/l is considered as vitamin d deficiency, and accordingly, effects of vitamin d supplementation will be easier to detect than if the included subjects were vitamin d sufficient. * hgb, sr, crp, creatinine \< 130 umol/l in males, \< 120 umol/l in females, calcium, ft4 and tsh within the normal reference range; asat \< 90 mu/l alat \< 140 u/l, hba1c \< 6.6 % * the subjects must agree not to take any vitamin d supplementation, including cod liver oil or "mølje", use solarium or go on sunny vacation during the intervention period. exclusion criteria: * subjects allergic to peanuts * subjects with primary hyperparathyroidism * granulomatous diseases (sarcoidosis, tuberculosis, wegner's granulomatosis) * diabetes * renal stones the last five years * subjects seriously ill (or with chronic disease) and unfit for participation in the study (as judged by one of the study doctors) * subjects using vitamin d supplements exceeding 800 iu per day or active vitamin d drugs (rocaltrol or etalpha) * pregnancy

Keywords: vitamin d
peanuts second meal glycemic response

Conditions: Type 2 Diabetes Mellitus

Summary: nut consumption is associated with reduced risk of type 2 diabetes. the aim of this study was to assess the effects of peanut (whole or peanut butter) to breakfast meals on glycemic, insulinemic and selected gut hormone responses, appetite, and food intake over two consecutive meals in obese women with high type 2 diabetes risk. fifteen women participated in a randomized crossover trial where 42.5g of whole peanuts (p), peanut butter (pb), or no peanuts (control-c) were added to a 75g available carbohydrate-matched breakfast meal. postprandial concentrations of blood glucose, insulin, non-esterified free fatty acids (nefa), glucagon-like peptide-1 (glp-1), peptide yy (pyy), cholecystokinin (cck), appetitive sensations and food intake were assessed after breakfast treatments and a standard lunch (75g available carbohydrate).


Eligibility criteria:
inclusion criteria: * body mass index between 30 - 35 kg/m2 * not taking medications known to affect glycemia, fat metabolism, or appetite * regular breakfast consumer (≥100 kilocalories ingested within 2 hours of waking on ≥4d/wk) * no body weight fluctuation (\<5kg in the past 3 months) * willingness to eat all test foods * no self-reported allergy to the foods provided in the study * no self-reported sleep disorders * at least one of the following conditions: waist circumference ≥ 88 cm; reported family history of type 2 diabetes in first degree relatives; capillary glycemia between 5.5 - 7.0 mmol/l; and/or a 2-hour blood glucose of 7.8 - 11.1 mmol/l (impaired glucose tolerance) exclusion criteria: * type 2 diabetes mellitus * dyslipidemia * high blood pressure

Keywords: peanut blood glucose insulin non-esterified free fatty acids glucagon-like peptide-1 peptide yy cholecystokinin appetitive food intake
evaluation of clinical effectiveness of roflumilast in routine practice, in chronic obstructive pulmonary disease (copd) patients in greece

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study was to examine the characteristics of patients selected for treatment with roflumilast and the effectiveness and safety of roflumilast in patients with severe or very severe copd treated in hospital and outpatient specialist ward settings in greece.

the drug being observed in this study is called roflumilast. roflumilast is used to treat people who have chronic obstructive pulmonary disease (copd) associated with chronic bronchitis with a history of worsening symptoms. this study looked at side effects and the lung function of people who take roflumilast. the study enrolled 2577 patients who were already prescribed roflumilast as an add on to bronchiodilator treatment by their healthcare provider. this multi-centre trial was conducted in greece. the overall time to participate in this study was up to 6 months. participants were evaluated during routine appointments with their healthcare provider.

Eligibility criteria:
inclusion criteria * be diagnosed with copd at stages 3 or 4 according to the global initiative for chronic obstructive lung disease (gold) guidelines. * have the clinical phenotype of chronic bronchitis with cough and sputum production (with or without emphysema). * already be receiving treatment for their disease (inhaled bronchodilators (long-acting beta2-agonists (laba), long-acting muscarinic antagonists (lama), short-acting beta2-agonists (saba), short-acting muscarinic antagonist (sama)), inhaled corticosteroids (ics), combination of inhaled bronchodilators and corticosteroids. * be aged over 40 years exclusion criteria: • none

Keywords: drug therapy
absorption of peptides, fluid, and electrolytes in patients with an ileostomy

Conditions: Nutritional Deficiency; Ileostomy; Functional Disturbance; Short Bowel Syndrome; Absorption; Disorder, Protein

Summary: clinical trial, active comparator, cross over, randomised. in total, 12 adults with an ileostomy will be randomised to a sequential 4 weeks intervention with different qualities and sources of protein wish 2-week washout periods. primary outcome: ileostomy output.

patients with an ileostomy may be dehydrated and have nutritional deficiencies secondary to malabsorption of fluid, electrolytes, and nutrients. in this randomised, double blinded, crossover intervention study we aim to investigate how different protein sources affect intestinal absorption in patients with an ileostomy and intestinal insufficiency. three oral solutions with different protein sources (hydrolysed whey, whey, and casein) will be administered in three different four-week intervention periods. the results will facilitate improved counselling and treatment of patients with an ileostomy.

Eligibility criteria:
inclusion criteria: * adult (≥ 18 years old), male or female patients with an ileostomy and intestinal insufficiency * episodical or chronic sodium depletion defined by two urine samples with sodium levels ≤ 20 mmol/l, sampled with at least 28 days apart * six months or more after most recent bowel surgery * if inflammatory bowel disease, no clinical signs of activity (any treatment allowed except systemic steroids \> 10 mg/day) exclusion criteria: * parenteral nutrition or intravenous fluid support ≥ 4000 ml/month * ongoing infection (c-reactive protein above 8 mg/l or core temperature \>38.0°c) * self-reported intolerance to dairy products, including lactose intolerance * inability to understand danish or the trial procedures * known or anticipated pregnancy * known severe renal insufficiency (egfr \< 20 ml/min) * known diabetes mellitus (hba1c ≥ 48 mmol/mol (6.5%)) * pacemaker, cochlear implants, or other electrical implants excludes the participants from bia-measurements and measurements of gitt with 3d-transit capsules, but not the remaining investigations * known intestinal stenosis or parastomal hernia excludes measurements of gitt with 3d-transit capsules, but not the remaining investigations * abdominal diameter \> 140 cm, or planned mr scan four weeks following participation excludes measurements of gitt with 3d-transit capsules, but not the remaining investigations
response to ranibizumab in polypoidal choroidal vasculopathy (pcv)and snps

Conditions: Polypoidal Choroidal Vasculopathy

Summary: to determine whether complement factor h (cfh) and age-related maculopathy susceptibility 2 (arms2) genotypes have a pharmacogenetic effect on the treatment of polypoidal choroidal vasculopathy (pcv) with ranibizumab.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of polypoidal choroidal vasculopathy * must have injection of ranibizumab exclusion criteria: -

Keywords: polypoidal choroidal vasculopathy ranibizumab
study of trans sodium crocetinate in patients with interstitial lung disease

Conditions: Interstitial Lung Disease

Summary: this is a randomized, placebo-controlled study of trans sodium crocetinate (tsc) in patients with interstitial lung disease (ild), age 30-85 (inclusive). the primary objective of the study is to determine the effect of tsc on lung function as measured by diffusing capacity of the lungs for carbon monoxide (dlco) in patients with ild; the secondary objectives are to determine the effect of tsc on the 6-minute walk test (6mwt), heart rate recovery (hrr), and borg scale in patients with ild.


Eligibility criteria:
inclusion criteria: 1. male or female, age 30 to 85 years at screening 2. able to provide informed consent and agree to adhere to all study visits and requirements 3. females of childbearing potential must have a negative blood pregnancy test at screening and agree to use one of the accepted contraceptive regimens, or a double method of birth control during the study and at least 30 days after the last dose of study drug 4. established diagnosis of ild (clinical, radiographic, or histologic) 5. spo2 ≥ 88% at rest by pulse oximetry while breathing ambient air 6. free of any active cardiovascular or neuromuscular disease, at pi discretion 7. clinically stable disease with no major medication changes in the last 4 weeks 8. forced vital capacity (fvc) ≥ 45% of predicted (within past 6 months) 9. dlco corrected for hemoglobin 30-90% of predicted, inclusive (within past 6 months) 10. sars-cov-2 negative at screening exclusion criteria: 1. known allergy to study medication 2. pregnancy or lactation 3. current smoker 4. inability to perform pulmonary function testing 5. active infection at screening or day of study visit 6. known pulmonary hypertension (ph) requiring ph-specific treatment 7. ast/alt ≥ 3x uln and/or total bilirubin ≥ 2x uln 8. received any investigational medicine (imp) within past 30 days 9. surgery or hospitalization in past 3 months determined by the pi to be clinically relevant. 10. current alcohol or substance abuse 11. known active or latent hepatitis b or c 12. history of end-stage liver or renal disease 13. positive covid test anytime within 3 months of screening. note: patients who were previously vaccinated for covid are allowed 14. history of venous thromboembolic disease 15. history of acute or chronic ophthalmologic conditions currently requiring treatment